Salivary Carcinoma, NOS
Associated Genetic Biomarkers
Salivary carcinoma, NOSs most frequently harbor alterations in TP53, EWSR1, ERBB2, SDHB, and CDKN2B .
TP53 Mutation, ERBB2 Amplification, TP53 c.217-c.1178 Missense, TP53 c.142-c.212 Missense, and TP53 c.1-c.137 Missense are the most common alterations in salivary carcinoma, NOS .
There is 1 clinical trial for salivary carcinoma, NOS, of which 1 is open and 0 are completed or closed. Of the trial that contains salivary carcinoma, NOS as an inclusion criterion, 1 is phase 2 (1 open).
ERBB2 is the most frequent gene inclusion criterion for salivary carcinoma, NOS clinical trials .
Nanoparticle-based paclitaxel suspension and trastuzumab are the most common interventions in salivary carcinoma, NOS clinical trials.
Significant Genes in Salivary Carcinoma, NOS
ERBB2 is mutated in 16.67% of salivary carcinoma, NOS patients .
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for salivary carcinoma, NOS, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary carcinoma, NOS as inclusion criteria, 1 is phase 2 (1 open) .
Nanoparticle-based paclitaxel suspension and trastuzumab are the most frequent therapies in salivary carcinoma, NOS trials with ERBB2 mutations as inclusion criteria .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.